AC Immune

The Alzheimer's drug development landscape has expanded significantly beyond anti-amyloid antibodies, with 88 different clinical trials currently recruiting patients and twelve Phase 3 trials expected to report results in 2025.

ACI-7104.056 active immunotherapy demonstrated strong immunogenicity in early Parkinson's disease patients, producing anti-alpha-synuclein antibody levels 20-fold higher than placebo after four immunizations.

AC Immune's Q3 2024 was marked by advancements in its ACI-7104.056 VacSYn Phase 2 trial for Parkinson's disease and a CHF 24.6 million milestone payment in an Alzheimer's Phase 2b trial.

Long-term use of some cardiovascular drugs is associated with a reduced risk of dementia, while anti-platelet use shows a higher dementia risk, according to Swedish data.

AC Immune's ACI-7104 vaccine demonstrates safety and tolerability in an early-stage Parkinson's disease Phase 2 trial.

AC Immune's stock surged by over 20% following positive interim data from its Phase II VacSYn trial of ACI-7104.056 for Parkinson's disease.

AC Immune's ACI-7104.056 immunotherapy demonstrated a significant increase in anti-alpha-synuclein antibodies in Parkinson's disease patients after six weeks.

• AC Immune's ACI-7104.056 Phase 2 trial for Parkinson's disease is set to report interim safety and immunogenicity data by the end of 2024. • Milestone payment of CHF 24.6 million was triggered by rapid prescreening for the Phase 2b Retain trial of JNJ-2056 in preclinical Alzheimer's disease. • JNJ-2056, an active immunotherapy, received Fast Track designation from the FDA for Alzheimer's disease, highlighting its potential impact. • AC Immune's cash position, bolstered by milestone payments, extends the company's financial runway into 2027, supporting ongoing research and development.

• Several pharmaceutical companies, including Roche, Johnson & Johnson, Sage Therapeutics, and Otsuka, have discontinued Alzheimer's and Parkinson's disease programs in 2024. • Roche terminated its collaboration with UCB and returned assets to AC Immune after disappointing clinical trial results for drugs like crenezumab and semorinemab. • Sage Therapeutics halted development of dalzanemdor in both Parkinson's and Alzheimer's after it failed to show efficacy in Phase II trials. • Despite these setbacks, experts suggest this isn't indicative of a major R&D shift, with Alzheimer's treatment projected to be a $15.5 billion market by 2031.

Roche has ended its collaboration with UCB, relinquishing rights to bepranemab, a Phase 2a Alzheimer's candidate, marking the second Alzheimer's partnership termination this year.